There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...

Stock analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Mersana Therapeutics in a note issued to ...

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

Archived replays will be available for approximately 90 days following the events. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody ...

Archive replays will be available for approximately 90 days following the events. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investigational PD-1 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...